저침습 흉부외과 수술 시장 - 세계 예측(2026-2032년)

The Minimally Invasive Thoracic Surgery Market is projected to grow by USD 5.18 billion at a CAGR of 8.35% by 2032.

Minimally invasive thoracic surgery (MITS) is reshaping the management of lung cancer, mediastinal disorders, pleural disease, esophageal conditions, pneumothorax, and benign thoracic pathology by reducing surgical trauma while preserving clinical effectiveness. The field spans video-assisted thoracoscopic surgery (VATS), robotic-assisted thoracic surgery (RATS), uniportal approaches, subxiphoid access, navigational bronchoscopy-assisted resection, enhanced imaging, and advanced energy and stapling technologies. Its adoption is supported by peer-reviewed evidence showing that minimally invasive approaches are commonly associated with shorter hospital stays, lower perioperative pain, faster functional recovery, fewer wound-related complications, and improved postoperative pulmonary preservation when compared with conventional open thoracotomy in appropriately selected patients. Demand is reinforced by rising lung cancer screening activity, a high burden of chronic respiratory disease, aging populations with higher surgical risk, and health-system pressure to improve operating room efficiency and reduce avoidable inpatient utilization. As thoracic programs expand, clinical excellence increasingly depends on multidisciplinary case selection, surgeon training, standardized perioperative pathways, and investment in imaging, anesthesia, instrumentation, and digital surgical planning.

Transformative Shifts in the Minimally Invasive Thoracic Surgery Landscape

The minimally invasive thoracic surgery landscape is moving from procedure-specific innovation toward integrated, digitally enabled care pathways. VATS remains a widely established platform for lobectomy, segmentectomy, wedge resection, thymectomy, pleural procedures, and sympathectomy, while robotic-assisted systems are gaining clinical relevance for complex dissections, suturing, and lymph node assessment due to enhanced dexterity, tremor filtration, three-dimensional visualization, and ergonomic advantages. A major shift is the rise of lung-sparing anatomical resections, particularly segmentectomy, supported by growing evidence and guideline recognition for selected early-stage non-small cell lung cancer cases. This has increased the importance of high-resolution computed tomography, three-dimensional reconstruction, intersegmental plane identification, fluorescence imaging, and precise nodule localization. Another transformative change is the convergence of diagnostics and therapy, with advanced bronchoscopy, cone-beam CT, electromagnetic or robotic navigation, and image-guided localization helping surgeons manage smaller and deeper pulmonary nodules detected through screening. Enhanced recovery after surgery protocols are also changing clinical economics by prioritizing opioid-sparing analgesia, early mobilization, chest-tube optimization, and faster discharge. At the same time, the specialty is addressing persistent barriers, including capital investment, unequal access to advanced platforms, learning-curve variability, reimbursement complexity, and the need for structured credentialing.

Cumulative Impact of Artificial Intelligence on Minimally Invasive Thoracic Surgery

Artificial intelligence is becoming a cumulative force across the minimally invasive thoracic surgery continuum, from screening and diagnosis to operative planning, intraoperative guidance, and postoperative surveillance. In lung cancer pathways, AI-enabled image analysis supports nodule detection, volumetric tracking, malignancy risk stratification, and workflow prioritization in radiology, helping clinicians manage growing imaging volumes created by low-dose CT screening programs. In surgical planning, machine learning and computer vision can assist with three-dimensional reconstruction, vascular and bronchial mapping, fissure assessment, and simulation-based rehearsal for anatomical resections. During procedures, AI is increasingly relevant for instrument tracking, surgical phase recognition, real-time decision support, automated documentation, and quality assessment, although clinical deployment requires rigorous validation, interoperability, cybersecurity, and human oversight. AI-enhanced robotics and digital platforms may improve consistency in complex minimally invasive thoracic procedures, but the strongest near-term value is likely to come from decision-support tools that reduce variability in patient selection, complication prediction, operating room scheduling, and recovery management. Responsible integration of AI requires transparent algorithms, representative datasets, bias monitoring, regulatory compliance, and clinician training so that automation strengthens, rather than replaces, surgical judgment.

Key Regional Insights Across Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

In Asia-Pacific, demand for minimally invasive thoracic surgery is supported by a high lung cancer burden in several countries, expanding cancer screening initiatives, growing tertiary hospital capacity, and rapid adoption of robotic and thoracoscopic techniques in advanced urban centers. China, Japan, South Korea, India, Australia, and Southeast Asian countries are strengthening thoracic oncology pathways through imaging access, multidisciplinary tumor boards, and training programs, though access remains uneven between metropolitan and rural settings. North America is characterized by mature minimally invasive thoracic surgery programs, broad use of VATS and robotic approaches, established lung cancer screening recommendations for high-risk populations, and strong emphasis on enhanced recovery and outpatient-oriented care where clinically appropriate. Latin America is seeing gradual expansion of minimally invasive thoracic procedures in major referral hospitals, with Brazil and Mexico acting as important clinical hubs; however, equipment affordability, specialist availability, and payer coverage continue to influence access. Europe benefits from guideline-driven cancer care, high participation in professional training networks, and strong public health systems that support standardized thoracic oncology services, although adoption patterns differ across Western, Southern, Central, and Eastern Europe. The Middle East is investing in specialized surgical centers, oncology infrastructure, and medical education, particularly in higher-income health systems, while Africa faces major constraints related to late diagnosis, limited specialist density, and restricted access to advanced operating platforms, even as regional centers develop capabilities in thoracic surgery and cancer care.

Key Group Insights for ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN is becoming increasingly relevant for minimally invasive thoracic surgery as Singapore, Thailand, Malaysia, Vietnam, Indonesia, and the Philippines expand thoracic oncology and advanced surgical services, with regional variation driven by hospital infrastructure, workforce training, and insurance coverage. The GCC is accelerating adoption through investments in high-acuity hospitals, cancer centers, robotic surgery programs, and international clinical collaboration, with a focus on reducing outbound medical travel and improving domestic specialty care. The European Union supports minimally invasive thoracic surgery through harmonized medical device regulation, cross-border clinical research, cancer screening initiatives, and professional education, although reimbursement and procurement mechanisms remain country-specific. BRICS countries represent a diverse set of opportunities and constraints: China and India have large patient populations and expanding surgical capacity, Brazil and South Africa serve as regional referral anchors, and Russia maintains advanced thoracic capabilities in major cities while facing geographic access challenges. The G7 includes several of the world's most established thoracic surgery ecosystems, with strong adoption of evidence-based cancer pathways, advanced imaging, robotic platforms, and clinical quality improvement initiatives. NATO member countries overlap with many high-income European and North American systems where military and civilian medical innovation, trauma experience, digital health infrastructure, and advanced surgical training can support procedural standardization and resilience in specialized thoracic care.

Key Country Insights Across Major Minimally Invasive Thoracic Surgery Markets

The United States has one of the most developed minimally invasive thoracic surgery environments, supported by lung cancer screening guidance, specialized cancer centers, robotic and VATS expertise, and enhanced recovery protocols. Canada emphasizes equitable access within publicly funded healthcare systems, with advanced thoracic surgery concentrated in major academic and regional referral centers. Mexico is expanding minimally invasive thoracic capabilities in private and public tertiary hospitals, particularly in large urban areas, while access differs by geography and payer type. Brazil is Latin America's key thoracic surgery hub, with strong academic expertise and growing use of VATS and robotic approaches in major centers, although resource distribution remains uneven. The United Kingdom benefits from national cancer pathways, thoracic surgery networks, and multidisciplinary care, with minimally invasive approaches integrated into lung cancer treatment for suitable patients. Germany has extensive hospital infrastructure, advanced surgical training, and broad use of endoscopic and robotic techniques in high-volume centers. France combines strong public hospital networks with oncology-focused care coordination, supporting minimally invasive procedures for lung and mediastinal disease. Russia has advanced thoracic surgery capacity in leading metropolitan institutions, while distance and regional infrastructure affect access outside major cities. Italy and Spain maintain strong thoracic surgery traditions, with VATS and robotic programs present in major academic and cancer hospitals. China is rapidly scaling minimally invasive thoracic surgery, supported by large case volumes, domestic clinical research, expanding robotic adoption, and increasing focus on early lung cancer detection. India is advancing through tertiary hospitals, private specialty centers, and growing surgeon training, but affordability and uneven infrastructure remain key constraints. Japan has long-standing expertise in thoracoscopic surgery, early lung cancer management, and technology-enabled precision procedures. Australia operates through specialized thoracic units with strong guideline-based care and screening policy development. South Korea is recognized for high adoption of minimally invasive and robotic thoracic techniques, strong cancer care infrastructure, and advanced digital health capabilities.

Actionable Recommendations for Minimally Invasive Thoracic Surgery Leaders

Industry leaders should prioritize evidence-led adoption rather than technology-led purchasing by aligning minimally invasive thoracic surgery investments with clinical indications, procedural volume, surgeon proficiency, and measurable patient outcomes. Hospitals and surgical networks should build structured training pathways that include simulation, proctorship, dual-console or team-based learning where available, and competency assessment for VATS, robotic-assisted surgery, and advanced bronchoscopy-linked workflows. Decision-makers should standardize enhanced recovery protocols, pain management, chest drainage strategies, and discharge criteria to reduce variation across thoracic programs. To support precision surgery, leaders should invest in integrated imaging, three-dimensional planning, nodule localization, fluorescence guidance, and interoperable data systems that connect radiology, pulmonology, anesthesia, pathology, oncology, and surgery. AI adoption should begin with validated use cases such as imaging workflow support, risk stratification, documentation, and quality analytics, accompanied by governance for bias, privacy, cybersecurity, and clinical accountability. Procurement teams should evaluate total procedural value, including instrument utilization, maintenance, training, operating room time, complication reduction, and pathway efficiency. Finally, health systems should expand access through hub-and-spoke referral models, tele-mentoring, regional training collaboratives, and outcome registries that track safety, equity, and long-term oncologic performance.

Research Methodology

This executive summary is developed using a structured secondary research approach grounded in verified clinical, regulatory, epidemiological, and healthcare-system sources. The methodology emphasizes peer-reviewed surgical literature, clinical practice guidelines, public health publications, cancer registry information, screening recommendations, medical device regulatory references, hospital pathway evidence, and consensus statements from recognized thoracic surgery, oncology, pulmonology, radiology, and anesthesia communities. Evidence was assessed for clinical relevance, recency, reproducibility, and applicability across procedure types such as VATS, robotic-assisted thoracic surgery, segmentectomy, lobectomy, mediastinal surgery, pleural procedures, and diagnostic-to-therapeutic lung nodule workflows. Regional, group, and country insights were synthesized from publicly available healthcare infrastructure indicators, cancer care policies, surgical capacity patterns, technology adoption signals, and access-related evidence without using market sizing, market share, or forecasting assumptions. The analysis avoids unsupported claims and distinguishes established clinical practice from emerging innovation, particularly in AI-enabled imaging, robotic surgery, and digital decision support. Findings are presented as an executive synthesis to support strategic decision-making, technology assessment, clinical program development, and policy-aware planning.

Conclusion

Minimally invasive thoracic surgery has become a central component of modern thoracic care, driven by the need for safer procedures, faster recovery, precision cancer treatment, and efficient healthcare delivery. The field is advancing through the combined impact of VATS, robotic-assisted surgery, advanced imaging, lung-sparing resections, enhanced recovery protocols, and AI-supported decision-making. Adoption is strongest where specialist training, multidisciplinary pathways, imaging infrastructure, and reimbursement alignment are well established, while disparities persist across regions with limited access to technology and thoracic expertise. The next phase of progress will depend on balancing innovation with evidence, expanding workforce capability, strengthening outcome measurement, and ensuring that digital tools and robotic platforms deliver clinically meaningful value. Organizations that invest in standardized care pathways, validated AI applications, advanced visualization, and equitable access models will be best positioned to improve outcomes in lung cancer and other thoracic diseases while supporting sustainable surgical transformation.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Minimally Invasive Thoracic Surgery Market, by Procedure Type

• 7.1. Introduction
• 7.2. Lung Resection
  • 7.2.1. Lobectomy
  • 7.2.2. Segmentectomy
  • 7.2.3. Wedge Resection
  • 7.2.4. Pneumonectomy
  • 7.2.5. Lung Volume Reduction Surgery
• 7.3. Esophageal Procedures
  • 7.3.1. Esophagectomy
  • 7.3.2. Anti-Reflux Surgery
  • 7.3.3. Myotomy
• 7.4. Mediastinal Procedures
  • 7.4.1. Thymectomy
  • 7.4.2. Mediastinal Tumor Resection
  • 7.4.3. Lymph Node Dissection
• 7.5. Pleural Procedures
  • 7.5.1. Pleurodesis
  • 7.5.2. Decortication
  • 7.5.3. Bullectomy
  • 7.5.4. Pleural Biopsy
• 7.6. Sympathetic Procedures

8. Minimally Invasive Thoracic Surgery Market, by Product Type

• 8.1. Introduction
• 8.2. Surgical Systems
  • 8.2.1. Thoracoscopic Video Systems
  • 8.2.2. Robotic Surgical Platforms
• 8.3. Surgical Instruments
  • 8.3.1. Endoscopic Hand Instruments
  • 8.3.2. Endoscopic Stapling Devices
  • 8.3.3. Energy Devices
    • 8.3.3.1. Electrosurgical Devices
    • 8.3.3.2. Ultrasonic Devices
    • 8.3.3.3. Advanced Bipolar Devices
  • 8.3.4. Suction-Irrigation Devices
• 8.4. Access Devices
  • 8.4.1. Trocars & Ports
  • 8.4.2. Access Needles
  • 8.4.3. Wound Protectors
• 8.5. Closure & Hemostasis Products
  • 8.5.1. Sutures & Clips
  • 8.5.2. Staple Line Reinforcement Materials
  • 8.5.3. Sealants & Hemostatic Agents
• 8.6. Imaging & Navigation
  • 8.6.1. Intraoperative Imaging Systems
  • 8.6.2. Fluorescence Imaging Systems
  • 8.6.3. Navigation & Mapping Systems

9. Minimally Invasive Thoracic Surgery Market, by Indication

• 9.1. Introduction
• 9.2. Malignant Thoracic Diseases
  • 9.2.1. Primary Lung Cancer
    • 9.2.1.1. Early-Stage Non-Small Cell Lung Cancer
    • 9.2.1.2. Locally Advanced Non-Small Cell Lung Cancer
  • 9.2.2. Metastatic Lung Lesions
  • 9.2.3. Esophageal Cancer
  • 9.2.4. Mediastinal Malignancies
• 9.3. Benign Thoracic Diseases
  • 9.3.1. Pneumothorax
  • 9.3.2. Empyema
  • 9.3.3. Benign Esophageal Disorders
    • 9.3.3.1. Gastroesophageal Reflux Disease
    • 9.3.3.2. Achalasia
  • 9.3.4. Mediastinal Cysts And Benign Tumors
  • 9.3.5. Hyperhidrosis
  • 9.3.6. Benign Pulmonary Nodules

10. Minimally Invasive Thoracic Surgery Market, by End User

• 10.1. Introduction
• 10.2. Hospitals
  • 10.2.1. Tertiary Care Hospitals
  • 10.2.2. Community Hospitals
  • 10.2.3. Specialty Thoracic Centers
• 10.3. Ambulatory Surgical Centers
• 10.4. Specialty Clinics
• 10.5. Academic And Research Institutes

11. Minimally Invasive Thoracic Surgery Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. Minimally Invasive Thoracic Surgery Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Minimally Invasive Thoracic Surgery Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Share Analysis, 2025
• 14.2. FPNV Positioning Matrix, 2025
• 14.3. Market Concentration Analysis, 2025
  • 14.3.1. Concentration Ratio (CR)
  • 14.3.2. Herfindahl Hirschman Index (HHI)
• 14.4. Recent Developments & Impact Analysis, 2025
• 14.5. Product Portfolio Analysis, 2025
• 14.6. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. B. Braun Melsungen AG
• 15.2. Becton, Dickinson and Company
• 15.3. Boston Scientific Corporation
• 15.4. Cardio Medical GmbH
• 15.5. CONMED Corporation
• 15.6. Cook Medical LLC
• 15.7. Dextera Surgical, Inc.
• 15.8. Fujifilm Holdings Corporation
• 15.9. GE HealthCare, Inc.
• 15.10. Grena Ltd.
• 15.11. Intuitive Surgical, Inc.
• 15.12. Johnson & Johnson
• 15.13. KARL STORZ SE & Co. KG
• 15.14. Koninklijke Philips N.V.
• 15.15. LivaNova plc
• 15.16. Medela Healthcare
• 15.17. Medtronic plc
• 15.18. Merit Medical Systems, Inc.
• 15.19. Olympus Corporation
• 15.20. Sklar Surgical Instruments
• 15.21. Smith & Nephew plc
• 15.22. Stryker Corporation
• 15.23. Teleflex Incorporated
• 15.24. Terumo Corporation